Page 124 - Haematologica-5

856
R. Bomben et al.
(AIRC), Investigator Grant IG-2015 (17622); “5x1000 Intramural Program”, Centro di Riferimento Oncologico, Aviano, Italy; Provincia Autonoma di Bolzano/Bozen, Italy; A.O. S. Maurizio, Bolzano/Bozen, Italy; Progetto di Rilevante Interesse Nazionale (PRIN2009) 7.07.02.60 AE01, Ministero Italiano dell'Università e della Ricerca (MIUR), Roma, Italy; Fondi di
Ricerca Locale, Università degli Studi di Torino, Italy; Fondazione Neoplasie Del Sangue (Fo.Ne.Sa), Torino, Italy; CRT 2015.1044, Fondazione CRT, Torino, Italy. We are grate- ful to all the Clinical Investigators, to the Pathologists, to Luigia Monitillo, Daniela Barbero, Marina Ruggeri, Paola Ghione, and Gian Maria Zaccaria.
References
1. Dreyling M, Ferrero S, Hermine O. How to manage mantle cell lymphoma. Leukemia. 2014;28(11):2117-2130.
2. Cheah CY, Seymour JF, Wang ML. Mantle Cell Lymphoma. J Clin Oncol. 2016; 34(11):1256-1269.
3. CampoE,SwerdlowSH,HarrisNL,PileriS, Stein H, Jaffe ES. The 2008 WHO classifica- tion of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019-5032.
4. Jares P, Colomer D, Campo E. Molecular pathogenesis of mantle cell lymphoma. J Clin Invest. 2012;122(10):3416-3423.
5. Dreyling M, Ferrero S, Vogt N, Klapper W. New paradigms in mantle cell lymphoma: is it time to risk-stratify treatment based on the proliferative signature? Clin Cancer Res. 2014;20(20):5194-5206.
6. Ghielmini M, Zucca E. How I treat mantle cell lymphoma. Blood. 2009;114(8):1469- 1476.
7. Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol. 2009;27(4):511-518.
8. ZuccaE,RoggeroE,PinottiG,etal.Patterns of survival in mantle cell lymphoma. Ann Oncol. 1995;6(3):257-262.
9. Barista I, Romaguera JE, Cabanillas F. Mantle-cell lymphoma. Lancet Oncol. 2001;2(3):141-148.
10. Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in man- tle-cell lymphoma. J Clin Oncol. 2009; 27(8):1209-1213.
11. Dreyling M, Ferrero S. The role of targeted treatment in mantle cell lymphoma: is trans- plant dead or alive? Haematologica. 2016;101(2):104-114.
12. Geisler CH, Kolstad A, Laurell A, et al. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in pre- dicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood. 2010;115(8):1530-1533.
13. Hoster E, Rosenwald A, Berger F, et al. Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. J Clin Oncol. 2016; 34(12):1386-1396.
14. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111(2):558-565.
15. Bea S, Valdes-Mas R, Navarro A, et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci USA. 2013;110(45):18250- 18255.
16. Zhang J, Jima D, Moffitt AB, et al. The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells. Blood. 2014;123(19):2988-2996.
17. Katzenberger T, Petzoldt C, Holler S, et al.
The Ki67 proliferation index is a quantita-
tive indicator of clinical risk in mantle cell lymphoma. Blood. 2006;107(8):3407. 31.
18. Hartmann E, Fernandez V, Moreno V, et al. Five-gene model to predict survival in man- tle-cell lymphoma using frozen or formalin-
fixed, paraffin-embedded tissue. J Clin 32. Oncol. 2008;26(30):4966-4972.
19. Ek S, Bjorck E, Porwit-MacDonald A, Nordenskjold M, Borrebaeck CA. Increased expression of Ki-67 in mantle cell lym- phoma is associated with de-regulation of several cell cycle regulatory components, as identified by global gene expression analy- 33. sis. Haematologica. 2004;89(6):686-695.
20. Rosenwald A, Wright G, Wiestner A, et al.
The proliferation gene expression signature
is a quantitative integrator of oncogenic events that predicts survival in mantle cell 34. lymphoma. Cancer Cell. 2003;3(2):185-197.
21. Mozos A, Royo C, Hartmann E, et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the
cyclin D1-negative subtype. Haematologica. 35. 2009;94(11):1555-1562.
22. Navarro A, Clot G, Royo C, et al. Molecular subsets of mantle cell lymphoma defined by
the IGHV mutational status and SOX11 expression have distinct biologic and clinical 36. features. Cancer Res. 2012;72(20):5307-
and canonical NF-kappaB activation in man- tle cell lymphoma. Blood. 2016; 128(1):82- 92.
Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507-516.
Cortellazzo S, Martelli M, Ladetto M, Ferrero S, Ciccone G, Evangelista A, et al. High dose sequential chemotherapy with rituximab and ASCT as first line therapy in adult MCL patients: clinical and molecular response of the MCL-0208 trial, a FIL study. Haematologica. 2015;100(s1):3.
Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization (WHO) classification of lym- phoid neoplasms. Blood. 2016; 127(20):2375-2390.
Bomben R, Gobessi S, Dal BM, et al. The miR-17-92 family regulates the response to Toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes. Leukemia. 2012;26(7):1584-1593.
Dal Bo M, D'Agaro T, Gobessi S, et al. The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regula- tion in chronic lymphocytic leukemia cells. Oncotarget. 2015;6(22):19102-19117. Draghici S, Khatri P, Martins RP, Ostermeier GC, Krawetz SA. Global functional profiling
5316. of gene expression. Genomics.
23. Majlis A, Pugh WC, Rodriguez MA, Benedict WF, Cabanillas F. Mantle cell lym- 37. phoma: correlation of clinical outcome and biologic features with three histologic vari-
ants. J Clin Oncol. 1997;15(4):1664-1671.
24. Wiestner A, Tehrani M, Chiorazzi M, et al.
Point mutations and genomic deletions in 38. CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. Blood. 2007;109(11):4599-4606.
25. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lym- 39. phoma: perspectives for new targeted thera- peutics. Nat Rev Cancer. 2007;7(10):750-
762. 40.
26. Determann O, Hoster E, Ott G, et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti- CD20 immunochemotherapy: results from
randomized trials of the European MCL 41. Network and the German Low Grade Lymphoma Study Group. Blood. 2008; 111(4):2385-2387.
27. Perez-Galan P, Dreyling M, Wiestner A. 42. Mantle cell lymphoma: biology, pathogene-
sis, and the molecular basis of treatment in
the genomic era. Blood. 2011;117(1):26-38.
28. Young RM, Staudt LM. Targeting pathologi-
cal B cell receptor signalling in lymphoid 43. malignancies. Nat Rev Drug Discov. 2013; 12(3):229-243.
29. Akhter A, Street L, Ghosh S, et al. Concomitant high expression of Toll-like receptor (TLR) and B-cell receptor (BCR) sig- 44. nalling molecules has clinical implications in mantle cell lymphoma. Hematol Oncol. 2015;35(1):79-86.
30. Saba NS, Liu D, Herman SE, et al. Pathogenic role of B-cell receptor signaling
2003;81(2):98-104.
Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowl- edge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545-15550. Scott DW, Abrisqueta P, Wright GW et al. New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin- Embedded Biopsies. J Clin Oncol. 2017; 35(15):1668-1677.
Nera KP, Kohonen P, Narvi E, et al. Loss of Pax5 promotes plasma cell differentiation. Immunity. 2006;24(3):283-293. Hadzidimitriou A, Agathangelidis A, Darzentas N, et al. Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases. Blood. 2011;118(11):3088-3095. Rickert RC. New insights into pre-BCR and BCR signalling with relevance to B cell malignancies. Nat Rev Immunol. 2013; 13(8):578-591.
Wang ML, Blum KA, Martin P, et al. Long- term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015; 126(6):739- 745.
Rahal R, Frick M, Romero R, et al. Pharmacological and genomic profiling iden- tifies NF-kappaB-targeted treatment strate- gies for mantle cell lymphoma. Nat Med. 2014;20(1):87-92.
Lenz G, Balasubramanian S, Goldberg J, Rizo A, Schaffer M, Phelps C, et al. Sequence variants in patients with primary and acquired resistance to ibrutinib in the phase 3 MCL3001 (RAY) trial. Haematologica. 2016;101(s1):155.
haematologica | 2018; 103(5)